Product Details
ERBITUX 2MG/ML 100ML SDV 1/EA
Manufacturer: Eli Lilly
MFG#: 66733-0958-23
NDC: 66733-0958-23
PID: 643340
1/EA
$3,368.55
In StockAdditional Information
| Product Name | Erbitux 2 mg/mL 100 mL SDV 1/Ea |
| Application | Antineoplastic Agent |
| Generic Drug Name | Cetuximab, Preservative-Free |
| Mechanism of Action | EGFR inhibitor blocking tumor growth |
| Strength | 2 mg/mL |
| Type | Intravenous |
| Volume | 100 mL |
| Administration Route | IV infusion only |
| Common Side Effects | Rash, infusion reactions, hypomagnesemia, diarrhea |
| Severe Reactions | Anaphylaxis, cardiopulmonary arrest, severe dermatologic toxicity |
| Premedication | Antihistamines to reduce infusion-related reactions |
| Monitoring | Electrolyte levels, infusion reactions, dermatologic toxicity |
| Infusion Time | Initial dose over 120 minutes, subsequent doses over 60 minutes |
| Container Type | Single-Dose Vial |
| Storage Requirements | Requires Refrigeration (2°C-8°C) |
| Indications | Metastatic colorectal cancer, head and neck squamous cell carcinoma |
Description
Erbitux (Cetuximab) 2 mg/mL is a monoclonal antibody used for the treatment of specific cancers. It targets the epidermal growth factor receptor (EGFR) to inhibit tumor growth and progression. The formulation is a sterile, preservative-free solution intended for intravenous administration. The 100 mL single-dose vial ensures accurate dosing and minimizes contamination risks.
This medication is indicated for use in metastatic colorectal cancer and head and neck squamous cell carcinoma. It is often administered in combination with chemotherapy or radiation therapy to enhance treatment efficacy. By blocking EGFR signaling, Erbitux interferes with cancer cell proliferation and survival. The regimen requires careful patient selection, including EGFR expression testing and RAS mutation status evaluation.
Common side effects include infusion reactions, rash, hypomagnesemia, and gastrointestinal disturbances. Severe reactions may involve respiratory distress, cardiopulmonary arrest, and severe skin toxicity. Close monitoring of electrolytes and infusion-related symptoms is necessary.
Frequently Asked Questions (FAQs)
The cost of ERBITUX 2MG/ML 100ML SDV 1/EA is $$3,368.55
ERBITUX 2MG/ML 100ML SDV 1/EA is manufactured by Eli Lilly.
You can purchase ERBITUX 2MG/ML 100ML SDV 1/EA on our website at https://supplies.pipelinemedical.com/product/detail/erbitux-sf-2mg-ml-100ml-646778